Pharminent

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment met its primary endpoint, improving ACR20 response at week 16 versus placebo in patients suffering from active psoriatic arthritis.
read more http://www.pharmafile.com/news/511386/celgenes-otezla-hits-primary-endpoint-psoriatic-arthritis-study

Filed under: Arthritis